Assistant Professor of Pharmacy Practice University of the Incarnate Word San Antonio , Texas, United States
Christine Lam, PharmD, BCPS, BCACP, CDCES, BCGP: No financial relationships to disclose
Aducanumab, lecanumab, donanemab, solanezumab, oh my! Anti-amyloid monoclonal antibodies (MABs) are exploding as new options to delay the progression of Alzheimer’s Disease. Attend this session to review the evidence related to anti-amyloid MABs, discuss safety considerations and better understand this class's coverage requirements.
Interpret evidence related to efficacy of anti-amyloid monoclonal antibodies approved or in the late-stage pipeline for people with Alzheimer’s Disease.
Compare and contrast evidence related to safety of anti-amyloid monoclonal antibodies approved or in the late-stage pipeline for people with Alzheimer’s Disease.
Explain requirements for coverage of anti-amyloid monoclonal antibodies and monitoring.
Discuss the role of anti-amyloid monoclonal antibody therapy in treating Alzheimer’s Disease.